Avalo Therapeutics (NASDAQ:AVTX) Now Covered by Analysts at Jefferies Financial Group

Stock analysts at Jefferies Financial Group started coverage on shares of Avalo Therapeutics (NASDAQ:AVTX) in a report released on Tuesday,Benzinga reports. The brokerage set a “buy” rating and a $23.00 price target on the stock. Jefferies Financial Group’s price target would indicate a potential upside of 201.44% from the stock’s current price.

Several other analysts have also commented on the company. Piper Sandler began coverage on Avalo Therapeutics in a report on Friday, February 28th. They issued an “overweight” rating and a $48.00 price objective on the stock. BTIG Research began coverage on shares of Avalo Therapeutics in a report on Thursday, December 19th. They issued a “buy” rating and a $40.00 price target for the company. Stifel Nicolaus initiated coverage on shares of Avalo Therapeutics in a report on Tuesday. They set a “buy” rating and a $36.00 price objective on the stock. Wedbush reiterated an “outperform” rating and issued a $18.00 target price on shares of Avalo Therapeutics in a research report on Thursday, March 20th. Finally, HC Wainwright restated a “neutral” rating on shares of Avalo Therapeutics in a research report on Thursday, March 20th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $33.00.

Avalo Therapeutics Price Performance

AVTX stock opened at $7.63 on Tuesday. Avalo Therapeutics has a 52-week low of $4.60 and a 52-week high of $34.46. The company’s 50-day simple moving average is $7.47 and its 200-day simple moving average is $9.13.

Institutional Investors Weigh In On Avalo Therapeutics

A number of large investors have recently made changes to their positions in AVTX. Tower Research Capital LLC TRC boosted its stake in Avalo Therapeutics by 998.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock worth $31,000 after buying an additional 3,754 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of Avalo Therapeutics during the 4th quarter valued at about $114,000. Walleye Capital LLC purchased a new stake in shares of Avalo Therapeutics in the fourth quarter valued at about $145,000. Northern Trust Corp acquired a new stake in Avalo Therapeutics during the fourth quarter worth about $168,000. Finally, Bank of Montreal Can purchased a new position in Avalo Therapeutics during the fourth quarter worth about $446,000. 87.06% of the stock is currently owned by hedge funds and other institutional investors.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.